Aneja Nikhil 4
4 · Aligos Therapeutics, Inc. · Filed Mar 11, 2026
Research Summary
AI-generated summary of this filing
Aligos (ALGS) Principal Accounting Officer Nikhil Aneja Receives Award
What Happened
Nikhil Aneja, Principal Accounting Officer of Aligos Therapeutics (ALGS), received a derivative grant of 9,450 shares on March 9, 2026. The grant shows an acquisition price of $0.00 (i.e., no cash paid). This is a company award (not a market purchase or sale) and does not represent an immediate sale or cash transaction.
Key Details
- Transaction date: March 9, 2026; Filing date: March 11, 2026 (filed within the typical 2-business-day Form 4 window).
- Grant: 9,450 shares; reported price: $0.00; total reported value: $0.00 (derivative award).
- Vesting/Exercise: Per footnote, 1/48th of the shares vest monthly starting March 9, 2026; fully vested and exercisable on the fourth anniversary, subject to continued service.
- Shares owned after transaction: Not specified in the provided filing details.
- Footnote of record: F1 describes the 48-month monthly vesting schedule (service condition applies).
Context
This is a grant/award of a derivative security that vests over four years — a common form of employee compensation intended to retain personnel. It is neither a buy nor a sell in the open market and does not by itself indicate the insider is altering their immediate exposure to the stock.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-03-09+9,450→ 9,450 totalExercise: $7.03Exp: 2036-03-09→ Common Stock (9,450 underlying)
Footnotes (1)
- [F1]1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.